Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting

Stock Information for Epizyme Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Epizyme Inc.

Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ONEM, EPZM, LION
SHAREHOLDER ALERT: Weiss Law Reminds WWE, DRE, MN, and EPZM Shareholders About Its Ongoing Investigations
SHAREHOLDER ALERT: Halper Sadeh LLP Investigates VMW, EGY, USAK, EPZM
Shareholder Alert - The M&A Class Action Firm Continues Investigating the Merger - FSTX, EPZM, STCN, SIMO, VMW, VHAQ
SHAREHOLDER ALERT: Weiss Law Reminds RFP, ZEN, RDUS, and EPZM Shareholders About Its Ongoing Investigations
INVESTIGATION NOTICE: Halper Sadeh LLP Investigates ZEN, VIVO, EPZM
EPIZYME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Epizyme, Inc. - EPZM

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.